

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 1 of 1

ATTY. DOCKET NO.

33714-US-PCT

APPLICATION NO. - 10/599697

Not yet known

APPLICANT

WAGNER ET AL.

FILING DATE

Group

10/05/2006

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
WW/	AA	5,545,636	8/13/96	Heath, Jr. et al.	514	214	10/18/94
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
WW/	AM	03/082859	10/9/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
WW/	AN	03/104222	12/18/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
WW/	AO	98/11105	3/19/98	WO			<input type="checkbox"/>	<input type="checkbox"/>
WW/	AP	0 470 490	2/12/92	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

WW/	AR	Bradshaw D et al., "Therapeutic Potential of Protein Kinase C Inhibitors". Agents and Actions, Birkhaeuser Verlag, Basel, CH, Vol. 38, pp. 135-147, (1993).
WW/	AS	Nixon J S et al., "Novel, potent and selective inhibitors of protein kinase C show oral anti-inflammatory activity.", Drugs Under Experimental And Clinical Research, Bioscience Ediprint Inc., Vol. 17, no. 8, pp. 389-393, (1991).
WW/	AT	Harris W et al., "Recent developments in protein kinase C inhibitors", Expert Opinion On Therapeutic Patents, United Kingdom, vol. 7, no. 1, pp. 63-68, (1997).

EXAMINER

Walter Webb/

DATE CONSIDERED

09/25/2007

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
33714-US-PCT  
APPLICATION NO.  
10/599,697  
APPLICANT  
WAGNER ET AL.  
FILING DATE  
OCTOBER 5, 2006

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
/WW/	AA	5,057,614	10/15/91	Davis et al.	548	466	2/6/89
/WW/	AB	6,284,783	9/4/01	Zhou et al.	514	414	6/9/99
/WW/	AC	6,153,641	11/28/00	Bergstrand et al.	514	414	9/8/97
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
/WW/	AM	95/17182	6/29/95	WO			<input type="checkbox"/>	<input type="checkbox"/>
/WW/	AN	98/04551	2/5/98	WO			<input type="checkbox"/>	<input type="checkbox"/>
/WW/	AO	0 940 142	10/6/99	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/WW/	AR	Jordon et al., "Differential effects of protein kinase C inhibitors on chemokine production in human synovial fibroblasts", British Journal of Pharmacology, Vol. 117(6), pp. 1245-1253 (1996).
/WW/	AS	Wendling et al., "Partial synergy of bisindolylmaleimide with apoptotic stimulus in antigen-specific T cells -implications for multiple sclerosis", Journal of Neuroimmunology, Vol. 103(1), pp. 69-75, (2000).
	AT	

EXAMINER

/Walter Webb/

DATE CONSIDERED

09/25/2007

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.